Description of the active substance:
This information is a reference and it is not enough that the drug has been prescribed by a doctor ..
The thrombolytic agent is a serine protease in the form of a single-stranded molecule with a molecular weight of 54,000 daltons, consisting of 2 polypeptide chains with molecular masses of 20 and 34 thousand Da, which are connected by a disulfide bridge. Specifically stimulates the conversion of profibrinolysin (plasminogen) to fibrinolysin (plasmin), an enzyme capable of lysing fibrin clots.
For IV administration: occlusion of coronary vessels (acute myocardial infarction).
For subconjunctival injection, parabulbar, into the anterior chamber of the eye, intravitreal: hyphema, hemophthalmus; preretinal, subretinal and intra-retinal hemorrhages; fibrinoid syndrome of different genesis; occlusion of the central artery of the retina and its branches; thrombosis of the central vein of the retina and its branches; prevention of adhesions in the postoperative period with antiglaucoma operations.
Introduce IV in the cardiac practice; subconjunctival, parabulbar, as well as in the anterior chamber of the eye, intravitreal - in ophthalmic practice.
Applied in appropriate dosage forms and according to special schemes.
Allergic reactions: skin manifestations, as well as edema and hyperemia of the facial skin on the side of drug administration, allergic tenonitis (chemosis, conjunctival hyperemia, decreased mobility of the eyeball).
From the cardiovascular system: a decrease in blood pressure.
From the coagulation system of the blood: bleeding of varying severity from the sites of punctures and surgical incisions.
The tendency to bleeding (including hemorrhagic diathesis, hemophilia, thrombocytopenia, etc.), an increased risk of bleeding (gastrointestinal bleeding up to 4 weeks, extensive surgery or extensive trauma up to 4 weeks, intracranial or intraspinal interventions prescription up to 8 weeks, head trauma up to 4 weeks), resuscitation (including cardiopulmonary resuscitation for more than 10 minutes), liver disease with severe hemostasis, puncture of large vessels (eg, subclavian a vein), diabetic hemorrhagic retinopathy, a condition after a hemorrhagic stroke (including in the anamnesis), an increase in systolic blood pressure to 180 mm Hg. and above or diastolic blood pressure to 110 mm Hg. and above, cardiogenic shock (class IV according to Killip), suspicion of aortic aneurysm separation, septic endocarditis, pregnancy, hypersensitivity to prourokinase.
PREGNANCY AND LACTATION
Contraindicated in pregnancy.
APPLICATION FOR VIOLATIONS OF THE FUNCTION OF KIDNEYS
Contraindicated in liver diseases with a marked violation of the hemostasis system.
With the development of arterial hypotension (systolic blood pressure less than 90 mm Hg) and bradycardia (heart rate less than 50 beats per minute), it is recommended to stop the administration of the drug before normalizing the parameters of blood pressure and heart rate. Cross reactions with streptoza-streptokinase and allergies in streptococcal allergies, as a rule, does not arise.
When performing surgical interventions against the background of prourokinase to reduce the risk of hemorrhage, the administration of etamzilate in a dose of 250-500 mg is recommended.
Use with caution in combination with other trobolitics.
When used simultaneously with prourokinase acetylsalicylic acid and anticoagulants, the risk of bleeding increases.